Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients
|ClinicalTrials.gov Identifier: NCT00448071|
Recruitment Status : Unknown
Verified December 2006 by Wolfson Medical Center.
Recruitment status was: Recruiting
First Posted : March 15, 2007
Last Update Posted : March 15, 2007
|Condition or disease||Intervention/treatment||Phase|
|Hypotension End Stage Renal Disease Intra Dialytic Hypotension||Drug: MTR107||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Phase II, Randomized Double Blind Placebo-Controlled, Dose Escalating Study to Determine Pharmacokinetic and Pharmacodynamic Effects of MTR107 in End-Stage Renal Disease (ESRD) Patients|
|Study Start Date :||May 2006|
|Estimated Study Completion Date :||March 2007|
- A descriptive pharmacokinetic / pharmacodynamic study. No primary end-points apply.
- Exploratory Efficacy Parameters:
- Number and type of medical interventions required for treatment of hypotension.
- Alleviation of symptoms associated with intradialytic hypotension.
- Efficiency of dialysis as reflected by Kt/V
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00448071
|Contact: Zeev Katzir, MD||972-3-5028211|
|Wolfson Medical Center||Recruiting|
|Holon, Israel, 58100|
|Contact: Zeev Katzir, MD 972-3-5028291 email@example.com|
|Principal Investigator: Zeev Katzir, MD|
|Asaf Harofeh Medical Center||Recruiting|
|Rishon Le Zion, Israel, 70300|
|Contact: Shay Efrati, MD 972-8-9778061|
|Principal Investigator: Shay Efrati, MD|
|Principal Investigator:||Zeev Katzir, MD||Wolfson Medical Center|
|Principal Investigator:||Shay Efrati, MD||Asaf Harofeh Medical Center|